Results 11 to 20 of about 6,484 (105)

Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy‐Refractory Testicular Tumors

The Oncologist, Volume 24, Issue 12, Page e1437-e1442, December 2019., 2019
Abstract Testicular cancer is one of the few tumor types that have not yet benefited from targeted therapy. Still no new active agents for treating this cancer have been identified over the past 15 years. Once patients are refractory to cisplatin‐based chemotherapy, they will be expected to die from testicular cancer.
Bijun Lian, Wenhui Zhang, Tiegong Wang, Qingsong Yang, Zepeng Jia, Huan Chen, Lei Wang, Jing Xu, Wei Wang, Kai Cao, Xu Gao, Yinghao Sun, Chengwei Shao, Zhiyong Liu, Jing Li   +14 more
wiley   +1 more source

Abstracts of the 79th Annual Meeting of the Japanese Cancer Association; 2020 Oct 1‐3; Hiroshima, Japan as Cancer Science, Supplement 1, Vol 112 (2021)

, 2021
Cancer Science, Volume 112, Issue S1, Page 1-1072, February 2021.
wiley   +1 more source

Development of a Pt(II) compound based on indocyanine green@human serum albumin nanoparticles: integrating phototherapy, chemotherapy and immunotherapy to overcome tumor cisplatin resistance

Rare Metals, Volume 43, Issue 11, Page 6006-6022, November 2024.
Graphical abstract AbstractCisplatin resistance is the main cause for the failure of cancer therapy. To solve the problem, we proposed to develop a novel human serum albumin (HSA) nanoplatform to integrate chemotherapy, photothermal therapy (PTT) and immunotherapy.
Xue‐Yu Man, Ze‐Wen Sun, Shan‐He Li, Gang Xu, Wen‐Juan Li, Zhen‐Lei Zhang, Hong Liang, Feng Yang   +7 more
wiley   +1 more source

MiRNA210通过NUPR1基因靶向调控喉癌多药耐药性的研究

Zhongguo shiyan zhenduanxue, 2019
目的研究miRNA210在喉癌多药耐药中的调控机制。方法采用荧光素酶报告基因载体实验验证并确定了miRNA210的靶基因,进而构建miRNA210抑制物载体,通过抑制miRNA210的表达,观察其对喉癌多药耐药的调控作用。结果 miRNA210靶基因为NUPR1,抑制miRNA210的表达,可明显增加喉癌细胞对化疗的敏感性,miRNA210可通过调控其靶基因的表达影响喉癌的多药耐药性。结论 miRNA210表达参与喉癌多药耐药的调控机制,以miRNA210为靶点的药物开发及逆转治疗有潜在应用前景。
何丹, 王苹, 李亚纯, 尹万忠
doaj  

Abstracts

Cancer Science, Volume 116, Issue S1, Page 1-1975, January 2025.
wiley   +2 more sources

DPC4基因转染对结肠癌SW480细胞的影响

Zhongguo shiyan zhenduanxue, 2012
目的研究DPC4基因转染对结肠癌SW480细胞的影响。方法建了表达DPC4基因的逆转录病毒pLXSN载体,转染SW480细胞和未转染的SW480细胞为对照。Western鉴定DPC4蛋白的表达,MTT法检测细胞增殖率。结果发现SW480/DPC4细胞较SW480/pLXSN、SW480/-细胞,生长明显减缓,经统计有显著差异 ...
谢忠士, 谭岩, 宋燕
doaj  

抑癌基因IL-24在乳腺癌细胞中的表达及意义

Zhongguo shiyan zhenduanxue, 2013
目的研究hIL-24（人白细胞介素24）对MDA-MB-231乳腺癌细胞的生长抑制作用。方法将pDC316-hIL-24-EGFP转染人乳腺癌MDA-MB-231细胞,用RT-PCR法、Western blot法检测IL-24基因在肿瘤细胞中的表达。结晶紫染色法检测IL-24基因的表达对乳腺癌细胞的生长抑制。RT-PCR检测侵袭、转移相关基因的转录。ELISA法检测VEGF、Ang-1的分泌水平。结果 IL-24基因可在MDA-MB-231细胞中成功转录及表达,并对乳腺癌细胞增殖有明显抑制作用 ...
李正祎, 李艳, 郭素红, 孙可欣, 李欣, 袁忠海   +5 more
doaj  

Abstracts of the 76th Annual Meeting of the Japanese Cancer Association; 2017 Sept 28‐30; Yokohama, Japan

, 2018
Cancer Science, Volume 109, Issue S1, Page 1-1325, January 2018.
wiley   +1 more source

同源盒基因在肝癌细胞和组织中表达特点的研究

Zhongguo shiyan zhenduanxue, 2009
目的探讨肝癌细胞和肝癌组织中同源盒基因（Homeobox genes）的表达特点及苯乙酸（PA）作用后肝癌细胞系SSMC-7721细胞HOX基因的表达变化。方法应用噻唑蓝（MTT）比色法,以0.25、0.5、1.0、2.0、4.0 mmol/L的PA作用于肝癌SSMC-7721细胞,分别于24、48、72 h对细胞增殖进行检测。设计不同的引物,将已知的22种HOX基因分为3组（P1、P2、P3）,应用半定量逆转录-聚合酶链反应（RT-PCR）检测应用PA前后3组HOX基因mRNA的表达水平 ...
孟子辉, 李航, 姜涛, 季德刚, 杨永生, 张学文   +5 more
doaj  

人胃癌耐药细胞的建立方法及意义

Zhongguo shiyan zhenduanxue, 2021
目的 建立人胃癌耐药细胞,为研究人胃癌耐药细胞的耐药机制以及为耐药肿瘤细胞的治疗提供耐药肿瘤细胞模型。方法 体外培养人胃癌细胞SGC-7901,用50μmol/L顺铂多次反复冲击,对冲击4次和6次的SGC-7901分别检测对顺铂的抑制率和多药耐药基因（MDR）及多药耐药特异基因片段的表达,并计算药物对细胞的半数抑制浓度（IC50）。结果 经4次和6次冲击后,受冲击的SGC-7901胃癌细胞对顺铂的抑制率明显高于亲本细胞,IC50为63.98μmol/L和66.34μmol/L,而亲本细胞SGC ...
刘玉侠, 齐红, 段北野, 付尧, 夏莉, 于鸿, 王斌   +6 more
doaj